Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Sodium valproate information hub
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Our committees
Who we are
What we do
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE TAs
NICE TAs
22/04/2020
TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
22/04/2020
TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer
22/04/2020
TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
21/04/2020
TA533: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
21/04/2020
TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
21/04/2020
TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
21/04/2020
TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
21/04/2020
TA597: Dapagliflozin with insulin for treating type 1 diabetes
21/04/2020
TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
21/04/2020
TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
21/04/2020
TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
21/04/2020
TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
21/04/2020
TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
21/04/2020
TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line
21/04/2020
TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
16/04/2020
TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
16/04/2020
TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
16/04/2020
TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
16/04/2020
TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
15/04/2020
TA627: Lenalidomide with rituximab for previously treated follicular lymphoma
12
13
14
15
16
17
18
19
20
21
22
Follow AWTTC: